Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Colorectal Cancer Treatment Market size was valued at USD 20.08 billion in 2024 and is expected to reach USD 34.28 billion by 2037, registering around 4.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of colorectal cancer treatment is assessed at USD 20.8 billion.
The rising prevalence of colorectal cancer globally, along with the growth in efficient treatment options, are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as the increasing advancement in diagnostic methods on a global level. As per American Cancer Society, in U.S, 101,420 new cases of colon cancer and 44,180 new cases of rectal cancer, were registered in 2019.
Colorectal Cancer Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Prevalence of Colorectal Cancer Globally
- Growth in Efficient Treatment Options
Challenges
- Expensive Colorectal Cancer Treatment Therapies
- Lack of Awareness About the Disease in Lower Economic Regions
Colorectal Cancer Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.20% |
|
Base Year Market Size (2024) |
USD 20.08 billion |
|
Forecast Year Market Size (2037) |
USD 34.28 billion |
|
Regional Scope |
|
Colorectal Cancer Treatment Segmentation
The market is segmented on the basis of treatment type into surgery, chemotherapy, immunotherapy, radiotherapy, targeted therapy, ablation and others, out of which, the targeted therapy segment is anticipated to grab the largest share by the end of 2021 on account of technological advancements and better efficiency of targeted therapy than other therapies, for the treatment of colorectal cancer. Moreover, there is a large availability of prominent targeted therapies, which is also projected to contribute to the growth of the segment during the forecast period.
On the basis of end-user, the general medical & surgical hospitals segment in the global colorectal cancer treatment market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that general medical & surgical hospitals possess well-developed healthcare infrastructure for the diagnosis and treatment of colorectal cancer.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment Type |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportColorectal Cancer Treatment Industry - Regional Synopsis
Geographically, the colorectal cancer treatment market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific industry is estimated to account for largest revenue share by 2037, owing to increasing awareness about colorectal cancer and need to develop innovative cancer treatment solutions in the region.
Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the high prevalence of colorectal cancer, accompanied by the presence of leading healthcare service providers in the region. Along with this, North America also has an increasingly ageing population, which is also expected to contribute to the market growth in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the market on account of the rise in colorectal cancer diagnostic tests and a large presence of individuals suffering from colorectal cancer in the region. As per an epidemiologic study from the European Union, in 2018, colorectal cancer was ranked second among the deaths from cancer in Europe, with 98000 deaths in men and 79,400 deaths in women.
Companies Dominating the Colorectal Cancer Treatment Landscape
- Genentech, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- F. Hoffman-La Roche AG
- Bristol Myers Squibb
- Sanofi
- Merck Sharp & Dohme Corp.
- Bayer AG
- Novartis AG
- Taiho Oncology, Inc.
In the News
Author Credits: Radhika Pawar
- Report ID: 3003
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
